Paris – 24 July 2020 – Euronext today congratulated Aptorum Group Limited (ticker code: APM on Euronext and Nasdaq), a biopharmaceutical company focusing on the development of novel therapeutics to address unmet medical needs globally, on its listing in the professional compartment of Euronext’s regulated market in Paris. Listed on Nasdaq since 2018, Aptorum is joining Euronext’s strong biotech franchise, which is now composed of 62 companies.
Aptorum Group is a pharmaceutical company dedicated to developing and commercialising novel therapeutics to tackle unmet medical needs. To date, Aptorum Group has a therapeutic development pipeline of over 15 drugs, including indications in orphan diseases, infectious diseases and metabolic diseases, a number of which are targeted to enter clinical trial phases in the future. Aptorum Group is also launching a women’s health supplement, dioscorea opposita bioactive nutraceutical tablets, to be marketed under the brand name NativusWell ®.
With presence in multiple locations in North America, Asia and the United Kingdom, Aptorum Group has access to a broad spectrum of research and development capabilities, and human capital. Aptorum Group has also established strong relationships and collaborations with leading academic institutions to propel therapeutic innovations.
Aptorum Group Limited listed through the admission to trading of its 7,950,986 Class A ordinary shares*. The admission price of Aptorum Group Limited was set at around €3.22 per share, being the closing price of APM on 23 July 2020. Market capitalisation of the class A shares was approximately €25.6 million on the day of listing.
During the Euronext IPO ceremony, Darren Lui, President and Executive Director of Aptorum Group said: “We are proud to list on Euronext Paris, a new important milestone for Aptorum Group, after our successful listing on Nasdaq. Europe is a key market for our future developments. I am confident that the cross-listing, in addition to enhancing the shareholder base, attracting collaborations and raising the company’s global recognition, will also help us in expanding our footprint in Europe and offer us new business opportunities to engage in research and development projects.”
*the Company’s issued share capital consists of 7,950,986 Class A ordinary shares and 22,437,754 Class B ordinary shares.
Caption: Darren Lui, President and Executive Director of Aptorum Group, and Sebastian Grabert, Business Development Manager Listing of Euronext, rang the bell to celebrate Aptorum’s listing.